Literature DB >> 27401154

Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion.

Tomohiro Kawaguchi1, Yukihiko Sonoda2, Ichiyo Shibahara1, Ryuta Saito1, Masayuki Kanamori1, Toshihiro Kumabe3, Teiji Tominaga1.   

Abstract

The prognosis of patients with WHO grade III gliomas is highly dependent on their genomic status such as the isocitrate dehydrogenase (IDH) 1/2 mutation and1p/19q co-deletion. However, difficulties have been associated with determining which tumors have certain genomic profiles by preoperative radiographical modalities, and the role of surgical resection in achieving better outcomes remains unclear. This retrospective study included 124 consecutive patients with newly diagnosed grade III gliomas. The genomic status of IDH1/2 and 1p/19q was analyzed in these patients. Tumors were then divided into 3 subgroups based on their genomic status; the IDH 1/2 mutation with the 1p/19q co-deletion (1p/19q co-del), the IDH 1/2 mutation without the 1p/19q co-deletion (non-1p/19q co-del), and the IDH 1/2 wild type (IDH wt). Survival times were compared between patients who underwent gross total resection and those who did not (GTR versus non-GTR). The relationships between genomic statuses and MR imaging characteristics such as ring-like or nodular enhancements by gadolinium, and very low intensity on T1-weighted images with blurry enhancements (T1VL) were also examined. Among all patients with grade III gliomas, GTR patients had longer median survival and progression-free times than those of non-GTR patients (undefined versus 87 months, p = 0.097, and 124 versus 34 months, p = 0.059, respectively). No significant differences were observed in survival between GTR and non-GTR patients in the 1p/19q co-del group (p = 0.14), or between GTR and non-GTR patients in the IDH wt group (26 and 27 months, p = 0.29). On the other hand, in non-1p/19q co-del group, survival was significantly longer in GTR patients than in non-GTR patients (undefined versus 77 months, p = 0.005). Radiographically, T1VL was detected in most tumors in the non-1p/19q co-del group (78.2 %), but only 6 (21.4 %) and 17 (41.5 %) tumors in the 1p/19q co-del and IDH wt groups, respectively. A correlation was not found between other genomic subgroups and MR imaging findings. Strict surgical removal is important to improve the prognosis of patients with grade III gliomas, especially for tumors with the IDH 1/2 mutation without the 1p/19q co-deletion. The MR finding of T1VL can be used to select candidates for more radical resection.

Entities:  

Keywords:  1p/19q; Glioma; IDH; Magnetic resonance imaging; Surgery; WHO grade III

Mesh:

Substances:

Year:  2016        PMID: 27401154     DOI: 10.1007/s11060-016-2201-2

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  44 in total

Review 1.  IDH mutation in glioma: new insights and promises for the future.

Authors:  Zorbey Turkalp; Jason Karamchandani; Sunit Das
Journal:  JAMA Neurol       Date:  2014-10       Impact factor: 18.302

2.  Volumetric extent of resection and residual contrast enhancement on initial surgery as predictors of outcome in adult patients with hemispheric anaplastic astrocytoma.

Authors:  G Evren Keles; Edward F Chang; Kathleen R Lamborn; Tarik Tihan; Chih-Ju Chang; Susan M Chang; Mitchel S Berger
Journal:  J Neurosurg       Date:  2006-07       Impact factor: 5.115

3.  Mutational landscape and clonal architecture in grade II and III gliomas.

Authors:  Hiromichi Suzuki; Kosuke Aoki; Kenichi Chiba; Yusuke Sato; Yusuke Shiozawa; Yuichi Shiraishi; Teppei Shimamura; Atsushi Niida; Kazuya Motomura; Fumiharu Ohka; Takashi Yamamoto; Kuniaki Tanahashi; Melissa Ranjit; Toshihiko Wakabayashi; Tetsuichi Yoshizato; Keisuke Kataoka; Kenichi Yoshida; Yasunobu Nagata; Aiko Sato-Otsubo; Hiroko Tanaka; Masashi Sanada; Yutaka Kondo; Hideo Nakamura; Masahiro Mizoguchi; Tatsuya Abe; Yoshihiro Muragaki; Reiko Watanabe; Ichiro Ito; Satoru Miyano; Atsushi Natsume; Seishi Ogawa
Journal:  Nat Genet       Date:  2015-04-13       Impact factor: 38.330

4.  A better surgical resectability of WHO grade II gliomas is independent of favorable molecular markers.

Authors:  Dominik Cordier; Catherine Gozé; Sabine Schädelin; Valérie Rigau; Luigi Mariani; Hugues Duffau
Journal:  J Neurooncol       Date:  2014-09-28       Impact factor: 4.130

5.  Histological growth patterns and genotype in oligodendroglial tumours: correlation with MRI features.

Authors:  Michael D Jenkinson; Daniel G du Plessis; Trevor S Smith; Kathy A Joyce; Peter C Warnke; Carol Walker
Journal:  Brain       Date:  2006-05-02       Impact factor: 13.501

6.  Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.

Authors:  Gregory Cairncross; Meihua Wang; Edward Shaw; Robert Jenkins; David Brachman; Jan Buckner; Karen Fink; Luis Souhami; Normand Laperriere; Walter Curran; Minesh Mehta
Journal:  J Clin Oncol       Date:  2012-10-15       Impact factor: 44.544

7.  Association of surgically acquired motor and language deficits on overall survival after resection of glioblastoma multiforme.

Authors:  Matthew J McGirt; Debraj Mukherjee; Kaisorn L Chaichana; Khoi D Than; Jon D Weingart; Alfredo Quinones-Hinojosa
Journal:  Neurosurgery       Date:  2009-09       Impact factor: 4.654

8.  An integrated genomic analysis of human glioblastoma multiforme.

Authors:  D Williams Parsons; Siân Jones; Xiaosong Zhang; Jimmy Cheng-Ho Lin; Rebecca J Leary; Philipp Angenendt; Parminder Mankoo; Hannah Carter; I-Mei Siu; Gary L Gallia; Alessandro Olivi; Roger McLendon; B Ahmed Rasheed; Stephen Keir; Tatiana Nikolskaya; Yuri Nikolsky; Dana A Busam; Hanna Tekleab; Luis A Diaz; James Hartigan; Doug R Smith; Robert L Strausberg; Suely Kazue Nagahashi Marie; Sueli Mieko Oba Shinjo; Hai Yan; Gregory J Riggins; Darell D Bigner; Rachel Karchin; Nick Papadopoulos; Giovanni Parmigiani; Bert Vogelstein; Victor E Velculescu; Kenneth W Kinzler
Journal:  Science       Date:  2008-09-04       Impact factor: 47.728

9.  IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group.

Authors:  Martin J van den Bent; Hendrikus J Dubbink; Yannick Marie; Alba A Brandes; Martin J B Taphoorn; Pieter Wesseling; Marc Frenay; Cees C Tijssen; Denis Lacombe; Ahmed Idbaih; Ronald van Marion; Johan M Kros; Winand N M Dinjens; Thierry Gorlia; Marc Sanson
Journal:  Clin Cancer Res       Date:  2010-02-16       Impact factor: 13.801

10.  IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas.

Authors:  Koichi Ichimura; Danita M Pearson; Sylvia Kocialkowski; L Magnus Bäcklund; Raymond Chan; David T W Jones; V Peter Collins
Journal:  Neuro Oncol       Date:  2009-05-12       Impact factor: 12.300

View more
  33 in total

1.  Radiotherapy Plus Procarbazine, Lomustine, and Vincristine Versus Radiotherapy Plus Temozolomide for IDH-Mutant Anaplastic Astrocytoma: A Retrospective Multicenter Analysis of the French POLA Cohort.

Authors:  Vincent Esteyrie; Caroline Dehais; Elodie Martin; Catherine Carpentier; Emmanuelle Uro-Coste; Dominique Figarella-Branger; Charlotte Bronniman; Damien Pouessel; Delphine Larrieu Ciron; François Ducray; Elizabeth Cohen-Jonathan Moyal; Pola Network
Journal:  Oncologist       Date:  2021-02-15

2.  Molecular Subtype Classification in Lower-Grade Glioma with Accelerated DTI.

Authors:  E Aliotta; H Nourzadeh; P P Batchala; D Schiff; M B Lopes; J T Druzgal; S Mukherjee; S H Patel
Journal:  AJNR Am J Neuroradiol       Date:  2019-08-14       Impact factor: 3.825

3.  Extent of Surgical Resection in Lower-Grade Gliomas: Differential Impact Based on Molecular Subtype.

Authors:  S H Patel; A G Bansal; E B Young; P P Batchala; J T Patrie; M B Lopes; R Jain; C E Fadul; D Schiff
Journal:  AJNR Am J Neuroradiol       Date:  2019-06-27       Impact factor: 3.825

4.  "Real world" use of a highly reliable imaging sign: "T2-FLAIR mismatch" for identification of IDH mutant astrocytomas.

Authors:  Rajan Jain; Derek R Johnson; Sohil H Patel; Mauricio Castillo; Marion Smits; Martin J van den Bent; Andrew S Chi; Daniel P Cahill
Journal:  Neuro Oncol       Date:  2020-07-07       Impact factor: 12.300

5.  Differential expression of the TWEAK receptor Fn14 in IDH1 wild-type and mutant gliomas.

Authors:  David S Hersh; Sen Peng; Jimena G Dancy; Rebeca Galisteo; Jennifer M Eschbacher; Rudy J Castellani; Jonathan E Heath; Teklu Legesse; Anthony J Kim; Graeme F Woodworth; Nhan L Tran; Jeffrey A Winkles
Journal:  J Neurooncol       Date:  2018-02-16       Impact factor: 4.130

6.  Sensitive and rapid detection of TERT promoter and IDH mutations in diffuse gliomas.

Authors:  Bill H Diplas; Heng Liu; Rui Yang; Landon J Hansen; Alexis L Zachem; Fangping Zhao; Darell D Bigner; Roger E McLendon; Yuchen Jiao; Yiping He; Matthew S Waitkus; Hai Yan
Journal:  Neuro Oncol       Date:  2019-03-18       Impact factor: 12.300

7.  Prediction of lower-grade glioma molecular subtypes using deep learning.

Authors:  Yutaka Matsui; Takashi Maruyama; Masayuki Nitta; Taiichi Saito; Shunsuke Tsuzuki; Manabu Tamura; Kaori Kusuda; Yasukazu Fukuya; Hidetsugu Asano; Takakazu Kawamata; Ken Masamune; Yoshihiro Muragaki
Journal:  J Neurooncol       Date:  2019-12-21       Impact factor: 4.130

8.  The prognostic value of maximal surgical resection is attenuated in oligodendroglioma subgroups of adult diffuse glioma: a multicenter retrospective study.

Authors:  Xiaojie Ding; Zheng Wang; Di Chen; Yinyan Wang; Zheng Zhao; Chongran Sun; Dikang Chen; Chao Tang; Ji Xiong; Lingchao Chen; Zhenwei Yao; Ying Liu; Xiaoqin Wang; Daniel P Cahill; John F de Groot; Tao Jiang; Yu Yao; Liangfu Zhou
Journal:  J Neurooncol       Date:  2018-09-11       Impact factor: 4.130

9.  Impact of the extent of resection on the survival of patients with grade II and III gliomas using awake brain mapping.

Authors:  Kazuya Motomura; Lushun Chalise; Fumiharu Ohka; Kosuke Aoki; Kuniaki Tanahashi; Masaki Hirano; Tomohide Nishikawa; Junya Yamaguchi; Hiroyuki Shimizu; Toshihiko Wakabayashi; Ryuta Saito
Journal:  J Neurooncol       Date:  2021-05-19       Impact factor: 4.130

Review 10.  Extent of Resection of Glioblastoma: A Critical Evaluation in the Molecular Era.

Authors:  Daniel P Cahill
Journal:  Neurosurg Clin N Am       Date:  2020-11-05       Impact factor: 2.509

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.